Shumin Liu
President Enduring Biotech
Seminars
Thursday 11th June 2026
Designing Molecules to Decouple Potency From CRS in Autoimmune T-Cell Engagers
11:30 am
- Discover how Y108 is a PEGylated CD3/CD19 T-cell engager derived from the clinically validated blinatumomab platform
- Outline how, by leveraging established PEGylation technology, JY108 is designed to reduce cytokine release syndrome and improve tissue penetration
- Examine preclinical studies in autoimmune disease models that support its potential as a novel B-cell depletion therapy for autoimmune indications
